Business Wire (Free subscription) | yesterday
BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) commends the Partnership for a Drug-Free America® on the second
Seeking Alpha (Free subscription) | yesterday
King Pharmaceuticals (KG) is expected to report Q2 earnings before market open Thursday Aug. 7, with a conference call scheduled for 11:00 am ET. Guidance Analysts are looking for a profit of 32c on revenue of $397.28M. The consensus is wide, 25c to 37c for EPS, and $361M to $423M for revenue, according to First Call. Complete Story »
Pharmalot (Free subscription) | 08/05/2008
Call-option trading in King was the busiest since September and its shares rose to a seven-month high on speculation Pfizer will buy the drugmaker, Bloomberg News reports. “There’s chatter about possible interest from Pfizer,” Frederic Ruffy, senior options strategist at WhatsTrading.com, tells Bloomberg. “People are positioning for some kind of catalyst in the short term.” Earlier [...]
Seeking Alpha (Free subscription) | 08/05/2008
Rebecca Engmann Darst co-authored this article. King Pharmaceuticals (KG) - Nebulous takeover rumor appears to be driving the option activity in King Pharmaceuticals – scuttle which would readily explain the 71% spike in implied volatility and increase in option trading to 44 times the normal level. Adding to the frenzy is the fact that King is due to report earnings in two days’ time, and while a...
Business Wire (Free subscription) | 07/24/2008
BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) reported today that the Company plans to announce its financial results for the second quarter ended June 30, 2008,
Seeking Alpha (Free subscription) | 06/26/2008
Aaron F. Barkoff submits: Last month, we reported that King Pharmaceuticals (KG) had filed a citizen petition that could delay final approval of numerous ANDAs for generic versions of Altace (ramipril), which were set to earn final approval on June 7. King's citizen petition asked FDA to require ANDA applicants for ramipril to file patent certifications with respect to newly-issued U.S. Patent No....
The Earth Times Online Newspaper (Free subscription) | 06/20/2008
BRISTOL, Tenn. - King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to provide a live webcast of its presentation scheduled for Monday, June 23, 2008, at 9:35 a.m., Eastern Daylight Time, at the Leerink Swann Pain Roundtable Conference at the Sofitel Hotel in New York, New York. The
Market Wire - Investment Opinion (Free subscription) | 06/17/2008
LONDON (MARKET WIRE) MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for ST JUDE MEDICAL (NYSE: STJ), KING PHARMACEUTICALS INC (NYSE:...
Market Watch (Free subscription) | 06/10/2008
BOSTON (MarketWatch) -- King Pharmaceuticals and partner Pain Therapeutics said Tuesday that they have filed for U.S. market approval of their new pain medication Remoxy. The product is a tamper-resistant version of the powerful painkiller oxycondone, also known by the brand name OxyContin. Oxycondone, which can be highly addictive if abused, is used to treat severe chronic pain. The companies said...
The Pittsburgh Business Times (Free subscription) | 06/09/2008
Mylan Laboratories Inc. said Monday that it received final approval from the U.S. Food and Drug Administration to sell a generic version of King Pharmaceuticals' insomnia drug Sonata. (KG) (MYL)
Controlled Greed (Free subscription) | 06/09/2008
If you haven't been already, that is. This week's installment of the Festival of Stocks is being hosted by George over at Fat Pitch Financials. I submitted my post from last week on buying King Pharmaceuticals (KG/NYSE). But whether or...
Business Wire (Free subscription) | 06/05/2008
Company analysis includes a history of King Pharmaceuticals, a business segment analysis of the segments King Pharmaceuticals operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the companys major competitors.
Controlled Greed (Free subscription) | 06/05/2008
King Pharmaceuticals (KG/NYSE) is the new portfolio position established today. I bought the stock at $9.98 per share and it closed at $9.99. King makes and markets prescription drugs. I got in at just a tad under stated book value,...
Seeking Alpha (Free subscription) | 05/27/2008
Aaron F. Barkoff submits: King Pharmaceuticals markets Altace (ramipril), which is indicated for the treatment of high blood pressure. Until last year, when the Federal Circuit invalidated King's compound patent on ramipril, King earned about $700 million annually from U.S. sales of Altace. Although Lupin was the ANDA filer who prevailed against King in the patent litigation, Cobalt Labs, as the first...
GuruFocus Updates (Free subscription) | 05/16/2008
George Soros reduced to his holdings in Pharmaceuticals company King Pharmaceuticals Inc. (KG) during the 3-months ended 2008-03-31 by 70.22%. His sale prices were between $ 0 and $ 0, with an estimated average price of $ 9.9. The impact to his portfolio due to this sale was 0.01 %. His still held 17220 shares as of 2008-03-31. As of last market close, the price of King Pharmaceuticals Inc. (KG) was...
